Related Experiment Video

Updated: Jun 3, 2026

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

[Preclinical trials of L-lysine-alpha-oxidase, an antitumor enzyme]

V M Podboronov, A E Kuzovnikov, A K Zaĭtseva

    Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]
    |March 16, 2011
    PubMed

    Insights

    L-lysine-alpha-oxidase from Trichoderma did not suppress the humoral immune response to protein antigens. This enzyme also showed no negative impact on delayed type hypersensitivity or leukocyte migration capacity.

    Area of Science:

    • Immunology
    • Enzymology
    • Microbiology

    Background:

    • The immune system's response to protein antigens is crucial for adaptive immunity.
    • Understanding the immunomodulatory effects of enzymes, such as L-lysine-alpha-oxidase, is important for potential therapeutic applications.

    Purpose of the Study:

    • To investigate the impact of L-lysine-alpha-oxidase from the Trichoderma genus on the humoral immune response.
    • To evaluate the enzyme's effect on delayed type hypersensitivity and leukocyte migration capacity.

    Main Methods:

    • Repeated intravenous administrations of L-lysine-alpha-oxidase (35 U/kg) were performed.
    • Humoral immune response to protein antigens was assessed.
    • Delayed type hypersensitivity to xenogenous erythrocytes and leukocyte migration capacity were measured.

    Main Results:

    • L-lysine-alpha-oxidase did not exhibit a depressive action on the humoral immunity.
    • The enzyme showed no suppressive effect on delayed type hypersensitivity.
    • Therapeutic or double doses of L-lysine-alpha-oxidase did not reliably affect leukocyte migration capacity.

    Conclusions:

    • L-lysine-alpha-oxidase from Trichoderma appears to be non-immunosuppressive concerning humoral immunity and cellular responses.
    • The enzyme's safety profile suggests potential for further investigation in immunological contexts.

    Related Concept Videos

    Antiprotozoal Agents01:21

    Antiprotozoal Agents

    Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...